Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Myeloma: real-world data

Evangelos Terpos • 15 Jun 2019
EHA 2019
Multiple Myeloma Dexamethasone Ixazomib Lenalidomide
INSIGHT-MM

Evangelos Terpos, MD, PhD, of University of Athens, Athens, Greece discusses how trial data corresponds to the real-world setting with regards to relapsed/refractory myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Evangelos Terpos

Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing
2:38
Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing
Evangelos Terpos • 12 May 2025
Advice for managing bone disease in multiple myeloma
3:25
Advice for managing bone disease in multiple myeloma
Evangelos Terpos • 12 May 2025
The potential of sustained MRD negativity to guide maintenance discontinuation post-SCT in myeloma
3:34
The potential of sustained MRD negativity to guide maintenance discontinuation post-SCT in myeloma
Evangelos Terpos • 12 May 2025
Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment
0:57
Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment
Evangelos Terpos • 6 Dec 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Evangelos Terpos • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Evangelos Terpos • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Evangelos Terpos • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Evangelos Terpos • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals